Stéphane Postic Email & Phone Number

Montpellier, Occitanie, France

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY®. We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

Lille Area, France

QUARTAM provides financial services to young innovative companies.

Paris, Ile-De-France, France

Egle Therapeutics is an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. Egle Therapeutics recently entered into a corporate strategic research alliance with Takeda Pharmaceutical Company Limited with the goal of validating novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.

Paris, Île-De-France, France

Paris Area, France

Da Volterra is a biopharmaceutical company based in Paris (France) that develops new strategies for the prevention and the treatment of multi-resistant and life-threatening infections for which the medical need is increasing. While infectious diseases and antibiotic resistance threatens current medical practice, Da Volterra’s innovative approaches promise a substantial medical progress to combat deadly pathogens.Its most advanced product, DAV132, is developed to prevent Clostridium difficile infections following antibiotic treatments. DAV132 has a novel and unique mechanism of action, aiming to protect the intestinal microbiota from damage made by antibiotics, by capturing the antibiotic residues responsible for the disruption on the intestinal flora in the late digestive tract, while maintaining their systemic efficacy. DAV132 is the first prophylactic product that prevents disruption of the microbiota by antibiotics, with a clinically demonstrated proof-of-concept in man.

Paris Area, France

H-Immune develops novel fully human antibody-based therapeutics with a strong focus on immuno-oncology. H-Immune is currently deploying its proprietary platform against a novel immune check point as part of its internal pipeline development program but intends to pursue additional strategic partnerships to further leverage its powerful IVI-based discovery engine.

Lille Area, France

OCR is specialized in the design and the monitoring of Comparative Medicine Studies of owned-Dogs with spontaneous cancers as natural animal models for assessment of drug candidates under development for Human Health.

Loos, France

NATURALPHA is a French company expert in Science, R&D and legislation applied to Nutrition and health products. We provide consulting services on science & regulation and clinical trials. Our expertise is dedicated to ingredients, food, dietary supplements, health foods, drugs and medical devices.

Accounting And Finance

Classe Préparatoire

Bac C